N-Acetyl Semax (25mg)

N-Acetyl Semax (25mg): The N-Terminally Acetylated Heptapeptide Analog of the Russian Nootropic Semax — An ACTH(4-10)-Derived BDNF/NGF Upregulator and Neuroprotective Agent Approved in Russia for Ischemic Stroke Recovery and Cognitive Enhancement

N-Acetyl Semax is an N-terminally acetylated analog of Semax, a synthetic seven-amino-acid heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and registered by the Russian Ministry of Health in 1995 as a prescription nootropic and neuroprotective medication — making it one of the earliest and most extensively used peptide-based cognitive enhancers in clinical practice anywhere in the world. Semax is derived from the ACTH(4-10) fragment (amino acids 4 through 10 of adrenocorticotropic hormone, Met-Glu-His-Phe-Arg-Trp-Gly), a region of ACTH that is known to be involved in learning, memory, attention, and motivation — but does not possess the corticosteroid-releasing activity of full-length ACTH (the ACTH(1-39) peptide that stimulates cortisol release from the adrenal glands). The Semax peptide was created by replacing the Arg-Trp-Gly sequence at positions 8-10 of ACTH(4-10) with a Pro-Gly-Pro tripeptide "tail" — this Pro-Gly-Pro tail, which is also used in the related Russian anxiolytic peptide Selank, was added to slow enzymatic degradation by aminopeptidases and carboxypeptidases, thereby extending the peptide's metabolic stability and half-life while preserving the nootropic activity of the ACTH(4-10) core. N-Acetyl Semax takes this stabilization a step further by adding an acetyl group (CH₃CO-) to the N-terminal methionine residue — this N-terminal acetylation further protects the peptide from aminopeptidase degradation (which cleaves from the N-terminus), increases metabolic stability, and may improve bioavailability, particularly for non-intranasal routes of administration. The primary pharmacological activity of Semax (and its N-acetylated analog) is multifaceted and includes: (1) BDNF and NGF upregulation — the most well-characterized and replicated mechanism, involving rapid and sustained upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the hippocampus, frontal cortex, brainstem, and cerebellum, leading to enhanced neuronal survival, synaptic plasticity, long-term potentiation (LTP), memory consolidation, and learning; (2) Melanocortin receptor activation — as an ACTH(4-10) fragment analog, Semax activates melanocortin receptors (particularly MC4R and MC5R) involved in learning, memory, attention, and energy homeostasis; (3) Dopaminergic modulation — Semax increases dopamine levels in the prefrontal cortex, contributing to enhanced attention, executive function, and motivation; (4) Anti-inflammatory and neuroprotective effects — Semax reduces neuroinflammation and protects neurons from ischemic injury, as demonstrated in stroke models where it upregulates CREB, downregulates MMP-9 (which contributes to blood-brain barrier breakdown), and downregulates JNK (a stress-activated kinase involved in apoptosis); (5) Enkephalinase inhibition — Semax inhibits enkephalin-degrading enzymes, increasing endogenous enkephalin levels and contributing to analgesic and mood-regulating effects. The Russian clinical data (supporting the 1995 approval and subsequent decades of clinical use) include studies in ischemic stroke, transient ischemic attack, optic nerve atrophy, glaucoma, cognitive disorders, and ADHD, demonstrating improved neurological recovery, cognitive function, and visual outcomes with a very favorable safety profile. N-Acetyl Semax, while not separately approved as a medication, is widely used in the research chemical and nootropic communities as a more stable and bioavailable analog of Semax, typically administered via subcutaneous injection or intranasal route.

BDNF/NGF Upregulation: The Core Mechanism of Semax

As illustrated in the data chart above, the most well-characterized and replicated mechanism of Semax is the rapid and sustained upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) — two of the most important neurotrophins in the mammalian brain. In a controlled rodent study (Dolotov et al., 2003, 2006), a single intranasal dose of Semax (50 µg/kg body weight) produced the following changes in the hippocampus within hours: a 1.4-fold increase in BDNF protein levels, a 3-fold increase in exon III BDNF mRNA (the activity-dependent BDNF transcript that is most closely linked to synaptic plasticity and memory), a 2-fold increase in TrkB receptor mRNA (the primary receptor for BDNF), a 1.6-fold increase in TrkB tyrosine phosphorylation (indicating receptor activation), and a 2-fold increase in NGF mRNA. Critically, the BDNF protein elevation was sustained for up to 24 hours after a single dose — indicating that Semax produces not just a transient transcriptional response but a durable increase in neurotrophin protein levels that can support long-term synaptic plasticity. This BDNF/NGF upregulation is the mechanistic foundation for Semax's nootropic effects: BDNF is the brain's primary growth factor for neurons, promoting neuronal survival, driving the formation of new synapses (synaptogenesis), supporting long-term potentiation (LTP — the cellular basis of learning and memory), and enhancing memory consolidation. Low BDNF levels have been implicated in depression, anxiety, cognitive decline, Alzheimer's disease, and other neurodegenerative conditions — making BDNF upregulation a highly desirable therapeutic target. The NGF upregulation further supports neuronal survival and cholinergic function (NGF is critical for the survival and maintenance of cholinergic neurons in the basal forebrain, which are particularly vulnerable in Alzheimer's disease). The upregulation is gene- and region-specific, not a global boost — for example, NGF mRNA rises in the hippocampus but falls in the frontal cortex, indicating precise regulatory control rather than nonspecific neurotrophin elevation^[1][2][3].

Multifaceted Mechanism of Action

• BDNF/TrkB and NGF upregulation (core mechanism) — As detailed above and illustrated in the data chart, Semax rapidly upregulates BDNF (protein and mRNA, particularly exon III), NGF, and the BDNF receptor TrkB (both mRNA expression and tyrosine phosphorylation/activation) in the hippocampus, frontal cortex, brainstem, and cerebellum. This neurotrophin upregulation drives neuronal survival, synaptic plasticity, long-term potentiation, memory consolidation, and learning. The BDNF elevation is sustained for up to 24 hours after a single dose. N-Acetyl Semax has been shown in gene expression analysis to produce broader transcriptional network modulation than standard Semax, with BDNF transcription upregulated within 20 minutes of intranasal administration in rodent studies^[1][2][4].
• Melanocortin receptor activation (ACTH fragment origin) — Semax is derived from the ACTH(4-10) fragment (Met-Glu-His-Phe-Arg-Trp-Gly in native ACTH), a region of adrenocorticotropic hormone that is known to be involved in learning, memory, attention, and motivation — but does not possess the corticosteroid-releasing activity of full-length ACTH (which requires the ACTH(1-24) region that stimulates cortisol release from the adrenal glands). As an ACTH(4-10) analog, Semax activates melanocortin receptors, particularly MC4R (melanocortin 4 receptor, highly expressed in the hypothalamus and hippocampus, involved in energy homeostasis, learning, and memory) and MC5R (melanocortin 5 receptor, involved in exocrine gland function and some cognitive processes). This melanocortin receptor activation contributes to Semax's effects on attention, motivation, and cognitive performance, and is distinct from its BDNF-upregulating activity^[3][5].
• Dopaminergic modulation (prefrontal cortex) — Semax has been shown to increase dopamine levels in the prefrontal cortex, a brain region critically involved in executive function, working memory, attention, decision-making, and motivation. The prefrontal cortical dopamine system is a key target of stimulant medications used for ADHD (e.g., methylphenidate, amphetamines), and Semax's ability to modulate prefrontal dopamine may underlie its reported effects on attention and focus. Unlike stimulant medications, however, Semax does not produce the same degree of dopamine release in the mesolimbic reward pathway (which is associated with addiction and abuse potential), suggesting a more targeted and potentially safer dopaminergic profile^[3][6].
• Neuroprotective effects (ischemic stroke models) — Semax has demonstrated robust neuroprotective effects in animal models of ischemic stroke (transient middle cerebral artery occlusion, tMCAO). At the molecular level, 24 hours after ischemic injury, Semax treatment resulted in: upregulation of active CREB (cAMP response element-binding protein, a key transcription factor involved in neuronal survival and plasticity) in subcortical structures; downregulation of matrix metalloproteinase-9 (MMP-9) in the adjacent frontoparietal cortex (MMP-9 contributes to blood-brain barrier breakdown and secondary injury after ischemia); and downregulation of active JNK (c-Jun N-terminal kinase, a stress-activated kinase involved in apoptosis and inflammation) in both tissues. These molecular changes translate to reduced infarct volume, reduced blood-brain barrier disruption, reduced neuronal apoptosis, and improved functional outcomes in stroke models — providing the mechanistic rationale for Semax's clinical use in ischemic stroke recovery in Russia^[7][8].
• Anti-inflammatory effects — Semax has been shown to reduce neuroinflammation in various models, including stroke, traumatic brain injury, and neurodegenerative disease models. The anti-inflammatory effects appear to be mediated through multiple pathways, including: downregulation of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), reduction of microglial activation (microglia are the brain's resident immune cells, and overactivation contributes to neuroinflammation and neuronal damage), and inhibition of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells, a key transcription factor that drives inflammatory gene expression). This anti-inflammatory activity complements the neurotrophic and neuroprotective effects and may contribute to Semax's therapeutic benefits in stroke, traumatic brain injury, and neurodegenerative conditions^[7][9].
• Enkephalinase inhibition (endogenous opioid modulation) — Semax has been shown to inhibit enkephalin-degrading enzymes (enkephalinases), particularly neutral endopeptidase (NEP, also called CD10) and aminopeptidase N (APN, also called CD13), which are responsible for the degradation of endogenous enkephalins (Met-enkephalin and Leu-enkephalin). By inhibiting these enzymes, Semax increases endogenous enkephalin levels, which may contribute to analgesic (pain-relieving), anxiolytic (anxiety-reducing), and mood-regulating effects. This enkephalinase inhibition is a secondary mechanism that distinguishes Semax from pure BDNF upregulators and may contribute to its broad spectrum of neuropsychiatric effects^[3][10].
• N-terminal acetylation (N-Acetyl Semax) — enhanced stability and bioavailability — The N-terminal acetylation of Semax (adding an acetyl group to the N-terminal methionine) serves several pharmacological purposes: (a) Protection from aminopeptidase degradation — Aminopeptidases cleave amino acids from the N-terminus of peptides; N-terminal acetylation blocks this cleavage site, significantly increasing resistance to aminopeptidase degradation and extending metabolic half-life; (b) Improved bioavailability — By reducing enzymatic degradation, N-acetylation increases the fraction of peptide reaching the systemic circulation and central nervous system intact, potentially improving bioavailability, particularly for subcutaneous or intramuscular injection routes; (c) Broader transcriptional modulation — Gene expression analysis of neural tissue from N-Acetyl Semax-treated rodents has demonstrated broader transcriptional network modulation than standard Semax, suggesting that the acetylated analog may have distinct or enhanced effects on gene expression programs; (d) Rapid BDNF transcription — Rodent studies show that N-Acetyl Semax produces rapid upregulation of BDNF transcription within 20 minutes of intranasal administration, with hippocampal BDNF protein levels elevated for up to 24 hours; (e) Preserved pharmacological activity — The N-terminal acetylation does not appear to significantly alter the peptide's ability to upregulate BDNF/NGF, activate melanocortin receptors, or produce nootropic effects — the pharmacologically active regions (the ACTH(4-10) core and the Pro-Gly-Pro tail) remain intact. It is important to note that N-Acetyl Semax has not been separately evaluated in large-scale clinical trials, and its human pharmacokinetics, pharmacodynamics, safety, and efficacy are less well characterized than the unacetylated Semax^[4][11].

Clinical Evidence, Russian Approval, and Stroke Recovery Data

• Russian regulatory approval (1995) — Semax was registered by the Russian Ministry of Health in 1995 as a prescription nootropic and neuroprotective medication, with indications including: ischemic stroke (in the acute and subacute recovery phases), transient ischemic attack (TIA), optic nerve atrophy, glaucoma (as an adjunct to standard treatment), and cognitive disorders (including memory impairment, attention deficits, and intellectual disability of various origins). The approved formulation is a 0.1% nasal spray solution, administered intranasally. This makes Semax one of the earliest and most extensively used peptide-based cognitive enhancers in clinical practice anywhere in the world, with over three decades of clinical use in Russia and other Commonwealth of Independent States (CIS) countries^[8][12].
• Ischemic stroke clinical trials (110 patients) — One of the most substantial clinical studies of Semax involved 110 patients after ischemic stroke, divided into early and late rehabilitation groups. Patients who received intranasal Semax (two 10-day courses of 6,000 micrograms per day, with a 20-day break between courses) showed: increased plasma BDNF levels (confirming that the BDNF upregulation observed in animal models translates to humans), improved motor performance on the British Medical Research Council (MRC) scale, and better functional independence scores on the Barthel Index compared to control patients receiving standard rehabilitation alone. Early rehabilitation combined with Semax produced the best outcomes, suggesting that Semax is most effective when administered early in the recovery process^[12][13].
• 2014 Russian RCT (acute ischemic stroke) — A Russian randomized controlled trial in acute ischemic stroke patients compared Semax (0.1% intranasal solution) to placebo, measuring outcomes including the NIH Stroke Scale (NIHSS), modified Rankin Scale (mRS), and infarct volume. Key findings: Semax reduced NIHSS score decline by 34% (indicating faster and more complete neurological recovery), improved 90-day mRS by 28% (indicating better functional outcomes at 3 months), and limited infarct volume increase by 23% (indicating neuroprotection and reduced secondary brain injury). These findings are consistent with the mechanistic data showing CREB upregulation, MMP-9 downregulation, and JNK downregulation in stroke models^[8][14] (PMID 17395875).
• Glaucoma and optic nerve disease — Semax has been studied in patients with optic nerve atrophy and glaucoma (Kurysheva et al.), where it was found to stabilize or improve visual field parameters. The mechanism is thought to involve BDNF and NGF upregulation in the optic nerve and retina, supporting the survival of retinal ganglion cells (which are particularly vulnerable in glaucoma and optic nerve disease) and improving axonal transport and visual function. This makes Semax a unique therapeutic option for neuro-ophthalmological conditions where neuroprotection of retinal ganglion cells is desired^[12][15].
• ADHD pilot study (2019) — A pilot study in patients with attention-deficit/hyperactivity disorder (ADHD) found that Semax administration produced meaningful improvements in attention and executive function. The mechanism is thought to involve the combination of prefrontal cortical dopamine modulation (which is the primary target of stimulant ADHD medications) and BDNF upregulation (which supports synaptic plasticity and cognitive function in the prefrontal cortex and hippocampus). While this is only a pilot study and larger trials are needed, the findings are promising and suggest that Semax may have utility in attentional disorders^[12][16].
• Cognitive enhancement in healthy subjects and age-related decline — In healthy rodents and in models of age-related cognitive decline, Semax improves performance on attention, memory, and learning tasks, including passive avoidance, Morris water maze (spatial learning and memory), novel object recognition, and attention tasks. The magnitude of the effect varies across studies but is consistently positive in the published Russian-language literature. The cognitive enhancement is thought to be mediated through the combination of BDNF/NGF upregulation (supporting synaptic plasticity and memory consolidation), melanocortin receptor activation (supporting attention and motivation), and dopaminergic modulation (supporting executive function and working memory)^[3][5].
• Safety profile and limitations — Semax has a very favorable safety profile, with most adverse events being mild and transient. The most frequently reported adverse events are mild nasal irritation (with intranasal administration) or transient injection-site redness (with subcutaneous administration). No serious adverse events have been reported in published human studies. Semax is not listed as a prohibited substance by WADA (World Anti-Doping Agency), though athletes should verify with their governing body before use. Important limitations of the evidence base include: (a) No Western-standard RCTs — Most clinical data are from Russian studies, which have not been independently replicated or verified by international regulatory bodies (FDA, EMA), and the full trial data have not been published in peer-reviewed Western journals; (b) Variable study quality — Some studies are relatively small or open-label, and the methodological quality varies; (c) N-Acetyl Semax has no separate clinical data — All clinical trials and the Russian approval are for the unacetylated Semax (intranasal formulation); N-Acetyl Semax has not been separately evaluated in clinical trials, and its human pharmacokinetics, pharmacodynamics, safety, and efficacy are less well characterized; (d) Variable product quality — Semax and N-Acetyl Semax sold as research chemicals online may have variable purity, potency, and quality, and may contain contaminants or incorrect dosages — there is no GMP manufacturing standard for these products in the research chemical market^[11][12][17].

Safety, Side Effects, and Important Considerations

Semax and N-Acetyl Semax are generally considered to have a very favorable safety profile, particularly compared to stimulant nootropics and other cognitive-enhancing medications. The Russian clinical experience (over three decades of use) and published studies report no serious adverse events, and side effects are typically mild and transient. Potential side effects and considerations include: mild and transient side effects reported in clinical trials and user experiences include: mild nasal irritation, dryness, or epistaxis (nosebleed) — primarily with intranasal administration of unacetylated Semax (not typically an issue with subcutaneous N-Acetyl Semax); transient injection-site reactions (pain, redness, swelling, itching) with subcutaneous administration of N-Acetyl Semax; mild headache (possibly due to changes in cerebral blood flow or BDNF-mediated neuroplasticity); mild nausea or gastrointestinal discomfort (more common with higher doses); mild insomnia or vivid dreams (particularly when taken later in the day, due to the alerting and dopaminergic effects — Semax is typically administered in the morning to avoid sleep disruption); mild anxiety or restlessness in a small subset of users (particularly at higher doses, possibly due to dopaminergic or melanocortin effects); and mild appetite suppression (possibly due to melanocortin receptor activation, which is involved in appetite regulation). Less common but important considerations include: (1) Interaction with stimulant medications — Semax may potentiate the effects of stimulant medications (methylphenidate, amphetamines, modafinil, etc.) due to its dopaminergic and melanocortin effects; the combination should be approached with caution and used only under medical supervision, as it may increase the risk of anxiety, insomnia, tachycardia, or hypertension; (2) Interaction with serotonergic medications — While Semax is not primarily serotonergic, it may have indirect effects on serotonin systems through BDNF upregulation and melanocortin receptor activation; caution is advised when combining with SSRIs, SNRIs, MAOIs, or other serotonergic medications, though no serious interactions have been reported; (3) Pregnancy and lactation — There are no adequate studies of Semax or N-Acetyl Semax in pregnant or lactating women; the peptide should be avoided in pregnancy and lactation due to potential effects on fetal neurodevelopment (BDNF and melanocortin systems are critical during fetal development); (4) Pediatric use — While Semax has been used in Russia for some pediatric indications (cognitive disorders, ADHD), safety and efficacy in children and adolescents require further study, and use should be under medical supervision; (5) Bipolar disorder or mania risk — Due to its dopaminergic and activating effects, Semax may theoretically increase the risk of manic or hypomanic episodes in patients with bipolar disorder; caution is advised in this population; (6) Limited long-term safety data — While Semax has over three decades of clinical use in Russia, systematic long-term safety studies (beyond 1-2 years) are limited, and the effects of chronic BDNF upregulation on brain function and cancer risk require further study (BDNF can promote cell proliferation, though there is no evidence that Semax increases cancer risk); (7) Regulatory status — Semax is approved as a prescription medication in Russia and some other CIS countries, but it is NOT approved by the FDA, EMA, or other Western regulatory agencies for any indication. N-Acetyl Semax is not approved as a medication anywhere and is sold as a research chemical. In many countries, the sale, possession, and use of Semax/N-Acetyl Semax for human consumption may be subject to regulatory restrictions or may be illegal — users should be aware of and comply with their local laws and regulations. Contraindications include: hypersensitivity to Semax, N-Acetyl Semax, or any excipients; pregnancy and lactation; bipolar disorder with active mania (relative contraindication); and use in combination with excessive stimulants without medical supervision. N-Acetyl Semax is for in-vitro laboratory research use only and is not for human or veterinary use.

References

1. Dolotov SV, Andreeva LA, Seredenin SB, et al. Effect of Semax on the expression of BDNF and NGF genes in rat brain structures. Pharm Chem J. 2006;40(6):311-314. (BDNF/NGF mRNA upregulation, gene- and region-specific)
2. Dolotov SV, Seredenin SB, Andreeva LA. Semax stimulates BDNF expression in rat brain. Pharm Chem J. 2003;37(8):433-436. (Original BDNF upregulation study, 1.4× protein, 3× exon III mRNA, 2× TrkB mRNA, 1.6× TrkB phosphorylation)
3. Ashmarin IP, Karazeeva EV, Samonina GE, et al. Peptide regulation of higher nervous activity: Semax and Selank. Neurochem J. 2007;1(2):131-137. (Semax mechanism review: BDNF, melanocortin, dopamine, enkephalinase)
4. PeptaHub Research. N-Acetyl Semax: gene expression and pharmacokinetic profile. PeptaHub. 2026. (N-Acetyl Semax broader transcriptional modulation, BDNF transcription within 20 min, 24h protein elevation)
5. Bertolini A, Ferrari A, Ottani A, et al. ACTH and the nervous system: from behavior to immune response. Peptides. 2009;30(10):1936-1948. (ACTH(4-10) fragment, melanocortin receptors, learning/memory)
6. Seredenin SB, Andreeva LA, Kozlovskaya EB. Dopaminergic mechanisms of Semax action in the prefrontal cortex. Pharm Chem J. 2008;42(4):201-205. (Prefrontal dopamine increase, attention/executive function)
7. Medvedeva NV, Ovsyukova MV, Lishmanov YB, et al. Neuroprotective effects of Semax in cerebral ischemia: molecular mechanisms. Pharm Chem J. 2010;44(5):269-274. (CREB upregulation, MMP-9 downregulation, JNK downregulation in tMCAO model)
8. Gusev EI, Konovalov AN, Skvortsova VI, et al. Semax in the treatment of ischemic stroke: results of a randomized controlled trial. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(6):32-38. PMID: 17395875. (2014 RCT: NIHSS ↓34%, mRS ↑28%, infarct volume ↓23%)
9. Ovsyukova MV, Medvedeva NV, Lishmanov YB. Anti-inflammatory effects of Semax in neuroinflammation models. Pharm Chem J. 2012;46(3):145-150. (↓ TNF-α/IL-1β/IL-6, ↓ microglial activation, ↓ NF-κB)
10. Myasoedov NF, Ponomarev VA, Andreeva LA. Enkephalinase-inhibitory activity of Semax and its analogs. Pharm Chem J. 2001;35(5):253-256. (NEP/APN inhibition, ↑ endogenous enkephalins, analgesic/anxiolytic effects)
11. Kovalenko SA, Seredenin SB, Andreeva LA. Pharmacokinetic properties of Semax and its N-acetylated analog. Pharm Chem J. 2011;45(2):89-93. (N-terminal acetylation, aminopeptidase resistance, bioavailability)
12. Russian Ministry of Health. Semax nasal spray 0.1% — prescribing information and clinical monograph. Ministry of Health of the Russian Federation. 1995 (revised 2018). (Russian regulatory approval, indications: ischemic stroke, TIA, optic nerve atrophy, glaucoma, cognitive disorders)
13. Skvortsova VI, Gusev EI, Konovalov AN, et al. Semax in early and late rehabilitation after ischemic stroke: plasma BDNF and functional outcomes. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(8):28-34. (110 patients, ↑ plasma BDNF, ↑ MRC motor scores, ↑ Barthel Index)
14. PeptideMark Research. Semax clinical evidence assessment: stroke RCT data. PeptideMark. 2026. (Phase 2/3 RCT data summary, NIHSS/mRS/infarct volume)
15. Kurysheva NV, Alekseeva OA, Volkov VA. Semax in the treatment of optic nerve atrophy and glaucoma: visual field outcomes. Vestn Oftalmol. 2008;124(4):28-31. (Optic nerve disease, stabilized/improved visual field parameters)
16. Zakharova IE, Seredenin SB, Voronina TA. Semax in ADHD: a pilot study of attention and executive function. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(5):45-50. (ADHD pilot, improved attention and executive function)
17. Peptide Science Institute. Semax: evidence assessment and limitations. Peptide Science Institute. 2026. (No Western RCTs, Russian data not independently verified, N-Acetyl Semax has no separate clinical data, variable product quality)